Mark A.  Meltz net worth and biography

Mark Meltz Biography and Net Worth

Mark joined us from Audentes Therapeutics where he was Senior Vice President and General Counsel and helped lead its sale to Astellas Pharma. Prior to joining Audentes, he was Executive Vice President and Chief Business Development and Legal Officer at PaxVax where he led the company’s Legal, Compliance, Government Affairs and Business Development functions and helped lead its sale to Emergent BioSolutions. Mark also held senior legal positions at Biogen and Novartis Vaccines and Diagnostics, and served as Counsel at the global law firm Bingham McCutchen (now part of Morgan Lewis), where his work focused on mergers and acquisitions, venture capital financing, securities regulation and general corporate matters. Mark holds a BA from Yale University and a JD from Boston College Law School.

How old is Mark A. Meltz?

Mr. Meltz is currently 50 years old. There are 3 older executives and no younger executives at Kinnate Biopharma. The oldest executive at Kinnate Biopharma is Dr. Richard Thomas Williams MBBS, Ph.D., Chief Medical Officer, who is 55 years old. Learn More on Mark A. Meltz's age.

How do I contact Mark A. Meltz?

The corporate mailing address for Mr. Meltz and other Kinnate Biopharma executives is , , . Kinnate Biopharma can also be reached via phone at 858-299-4699 and via email at [email protected]. Learn More on Mark A. Meltz's contact information.

Has Mark A. Meltz been buying or selling shares of Kinnate Biopharma?

Mark A. Meltz has not been actively trading shares of Kinnate Biopharma over the course of the past ninety days. Learn More on Mark A. Meltz's trading history.

Who are Kinnate Biopharma's active insiders?

Kinnate Biopharma's insider roster includes Nima . (Pres), Carl Gordon (Director), Neha Krishnamohan (CFO), and Mark Meltz (COO). Learn More on Kinnate Biopharma's active insiders.

Are insiders buying or selling shares of Kinnate Biopharma?

In the last year, Kinnate Biopharma insiders bought shares 4 times. They purchased a total of 3,326,815 shares worth more than $9,074,491.04. The most recent insider tranaction occured on May, 8th when Director James B Tananbaum bought 1,780,000 shares worth more than $4,984,000.00. Insiders at Kinnate Biopharma own 41.7% of the company. Learn More about insider trades at Kinnate Biopharma.

Information on this page was last updated on 5/8/2023.

Mark A. Meltz Insider Trading History at Kinnate Biopharma

See Full Table

Mark A. Meltz Buying and Selling Activity at Kinnate Biopharma

This chart shows Mr. Mark A. Meltz's buying and selling at Kinnate Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kinnate Biopharma Company Overview

Kinnate Biopharma logo
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Read More

Today's Range

Now: $2.66
Low: $2.65
High: $2.69

50 Day Range

MA: $2.47
Low: $2.24
High: $2.66

2 Week Range

Now: $2.66
Low: $1.04
High: $7.18

Volume

518,478 shs

Average Volume

372,168 shs

Market Capitalization

$125.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36